Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07612267 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication

Name: A Study to Measure Mirikizumab Levels in Breast Milk of Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication — clinical trial record (NCT07612267)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorEli Lilly and Company

Started2026-08-05

View on ClinicalTrials.gov ↗

The main purpose of this study is to assess the amount of mirikizumab in breast milk in women who are breastfeeding who are receiving stable maintenance doses of mirikizumab for an approved indication. Participation in this study could last up to 94 days, including screening and follow-up period.

Amendment history 1 change detected by DataLookout

2026-08-21

Recruitment opened

Trial Details

NCT Number	NCT07612267
Lead Sponsor	Eli Lilly and Company
Conditions	Lactation, Inflammatory Bowel Disease
Enrollment	14 participants
Start Date	2026-08-05
Primary Completion	2028-09 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2026-08-20